These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30731492)

  • 21. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events.
    Pivatto Junior F; Scheffel RS; Ries L; Wolkind RR; Marobin R; Barkan SS; Amon LC; Biolo A
    Arq Bras Cardiol; 2017 Apr; 108(4):290-296. PubMed ID: 28538758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry.
    Del-Toro-Cervera J; Demelo-Rodriguez P; Galeano-Valle F; Fidalgo Á; Sampériz Á; Muñoz-Torrero JFS; Lima J; Sigüenza P; Tufano A; Monreal M;
    Thromb Res; 2020 Oct; 194():178-182. PubMed ID: 32788113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis.
    van Miert JHA; Bos S; Veeger NJGM; Meijer K
    PLoS One; 2018; 13(3):e0194208. PubMed ID: 29534092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes AC; Martins C; João I; Pereira H
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):972-6. PubMed ID: 26083988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Kooistra HA; Gebel M; Sahin K; Lensing AW; Meijer K
    Thromb Haemost; 2015 Nov; 114(6):1136-43. PubMed ID: 26224199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea.
    Szymanski FM; Lip GY; Filipiak KJ; Platek AE; Karpinski G
    Int J Cardiol; 2016 Feb; 204():200-5. PubMed ID: 26670173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism.
    Ambrus DB; Reisman JI; Rose AJ
    Thromb Res; 2016 Aug; 144():21-6. PubMed ID: 27270218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SAMe-TT
    Bernaitis N; Badrick T; Anoopkumar-Dukie S
    J Thromb Thrombolysis; 2020 Oct; 50(3):614-618. PubMed ID: 32080812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
    Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
    Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
    Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
    Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
    Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of SAMe-TT
    Wang K; Lu Y; Simegn MA; Xue H; Asinger RW
    J Thromb Thrombolysis; 2023 Jan; 55(1):175-180. PubMed ID: 36352057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial].
    Couturaud F; Pernod G; Pison C; Mismetti P; Sanchez O; Meyer G; Parent F; Girard P; Simonneau G; Drouet L; Gueret P; Jego P; Delaval P; Duhamel E; Gruel Y; Delahousse B; Regina S; Pottier P; Connaud J; Lecomte F; Provost K; Vilmans N; Gosset X; Bura-Rivière A; Meach G; Lacut K; Bosson JL; Guillot K; Mottier D; Leroyer C
    Rev Mal Respir; 2008 Sep; 25(7):885-93. PubMed ID: 18946418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.